Efficacy of High-precision Transcranial Direct Current Stimulation on Anxiety Disorders
Efficacy of High-precision Transcranial Direct Current Stimulation on Anxiety Disorders
ClinicalTrials.gov ID
NCT06529341
Lead Sponsor
Nanjing Medical UniversityOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Not Applicable
Enrollment
60Estimated
Last Update Posted
Jul 31, 2024Actual
Start Date
Jul 30, 2024Estimated
Primary Completion Date
Jul 30, 2025Estimated
Completion Date
Dec 30, 2025Estimated
Official Title
Efficacy of High-precision Transcranial Direct Current Stimulation on Anxiety Disorders
Brief Summary
Current research has found that tDCS has a positive effect on improving the negative attention bias of AD patients, and this study uses HD-tDCS intervention to improve the cognitive function and neural mechanisms of AD patients in the OFC to provide a theoretical basis for AD neural mechanism research. Verify Hypothesis 1: HD-tDCS cathodal stimulation of the left OFC reduces the excitability of this region, modulates its connectivity with the attentional function network, and thus changes the emotional experience of social threat.
Currently, there is no consensus on the stimulation parameters for tDCS in the treatment of AD, and more evidence is needed to prove and explore. It is hoped that the HD-tDCS intervention protocol will become an effective treatment method for improving cognitive function and clinical symptoms in AD patients. Hypothesis 2: The HD-tDCS with intensified stimulation parameters (2mA, twice a day, with a 20-minute interval, for 5 consecutive days) has an impact on the main and secondary clinical variables of AD patients.
Anxiety Disorders
High-definition Transcranial Direct Current Stimulation
High-definition transcranial direct current stimulation
High-definition transcranial direct current stimulation pseudo-stimulation control group
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Meet the DSM-5 AD diagnostic criteria;
The Chinese version of the Brief International Neuropsychiatric Interview (MINI) screening meets the diagnosis;
Age: 18-55 years old;
The patient participated voluntarily, obtained the consent of the family members, and signed the informed consent form;
Scale score criteria: 14 points on the Hamilton Anxiety Scale (HAMA) and 17 points on the Hamilton Depression Scale (HAMD).
Exclusion Criteria:
Neurological diseases or other psychiatric disorders;
severe somatic diseases;
received medical treatment including medication, psychotherapy, electroconvulsive therapy, and physical therapy within the first half months of enrollment;
tDCS examination contraindications, such as intracranial metal or electronic implants, skull plate, or other skull implants.